116. Yu Q, Yu X, Zhao W, Zhu M, Wang Z, Zhang J, Huang M, Zeng X (2018) Inhibition of
H3K27me3 demethylases attenuates asthma by reversing the shift in airway smooth muscle
phenotype. Clin Exp Allergy 48:1439–1452. https://doi.org/10.1111/cea.13244
117. Dela Cruz CS, Tanoue LT, Matthay RA (2011) Lung cancer: epidemiology, etiology, and
prevention. Clin Chest Med 32:605–644. https://doi.org/10.1016/j.ccm.2011.09.001
118. Luszczek W, Cheriyath V, Mekhail TM, Borden EC (2010) Combinations of DNA
methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung
cancer cells: correlation of resistance with IFN-stimulated gene expression. Mol Cancer Ther
9:2309–2321. https://doi.org/10.1158/1535-7163.MCT-10-0309
119. Suraweera A, O’Byrne KJ, Richard DJ (2018) Combination therapy with histone deacetylase
inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of
HDACi. Front Oncol 8:1–15. https://doi.org/10.3389/fonc.2018.00092
120. Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, Sebree R,
Rodgers K, Hooker CM, Franco N, Lee B, Tsai S, Delgado IE, Rudek MA, Belinsky SA,
Herman JG, Baylin SB, Brock MV, Rudin CM (2011) Combination epigenetic therapy has
efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov
1:598–607. https://doi.org/10.1158/2159-8290.CD-11-0214
121. Langevin SM, Kelsey KT (2017) Clinical epigenetics of lung cancer. Elsevier, Amsterdam
122. Qiu X, Liang Y, Sellers RS, Perez-Soler R, Zou Y (2016) Toxicity and pharmacokinetic
studies of aerosolized clinical grade azacitidine. Clin Lung Cancer 17:214–222e1. https://doi.
org/10.1016/j.cllc.2015.09.005
123. Little AG, Gay EG, Gaspar LE, Stewart AK (2007) National survey of non-small cell lung
cancer in the United States: epidemiology, pathology and patterns of care. Lung Cancer
57:253–260. https://doi.org/10.1016/j.lungcan.2007.03.012
Acetylation and Methylation in Asthma, COPD, and Lung Cancer
453
H3K27me3 demethylases attenuates asthma by reversing the shift in airway smooth muscle
phenotype. Clin Exp Allergy 48:1439–1452. https://doi.org/10.1111/cea.13244
117. Dela Cruz CS, Tanoue LT, Matthay RA (2011) Lung cancer: epidemiology, etiology, and
prevention. Clin Chest Med 32:605–644. https://doi.org/10.1016/j.ccm.2011.09.001
118. Luszczek W, Cheriyath V, Mekhail TM, Borden EC (2010) Combinations of DNA
methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung
cancer cells: correlation of resistance with IFN-stimulated gene expression. Mol Cancer Ther
9:2309–2321. https://doi.org/10.1158/1535-7163.MCT-10-0309
119. Suraweera A, O’Byrne KJ, Richard DJ (2018) Combination therapy with histone deacetylase
inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of
HDACi. Front Oncol 8:1–15. https://doi.org/10.3389/fonc.2018.00092
120. Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, Sebree R,
Rodgers K, Hooker CM, Franco N, Lee B, Tsai S, Delgado IE, Rudek MA, Belinsky SA,
Herman JG, Baylin SB, Brock MV, Rudin CM (2011) Combination epigenetic therapy has
efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov
1:598–607. https://doi.org/10.1158/2159-8290.CD-11-0214
121. Langevin SM, Kelsey KT (2017) Clinical epigenetics of lung cancer. Elsevier, Amsterdam
122. Qiu X, Liang Y, Sellers RS, Perez-Soler R, Zou Y (2016) Toxicity and pharmacokinetic
studies of aerosolized clinical grade azacitidine. Clin Lung Cancer 17:214–222e1. https://doi.
org/10.1016/j.cllc.2015.09.005
123. Little AG, Gay EG, Gaspar LE, Stewart AK (2007) National survey of non-small cell lung
cancer in the United States: epidemiology, pathology and patterns of care. Lung Cancer
57:253–260. https://doi.org/10.1016/j.lungcan.2007.03.012
Acetylation and Methylation in Asthma, COPD, and Lung Cancer
453